Trade Sage Therapeutics, Inc. - SAGE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.98 |
| Open | 4.99 |
| 1-Year Change | -77.49% |
| Day's Range | 4.92 - 5.59 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 5.59 | 0.62 | 12.47% | 4.97 | 5.59 | 4.90 |
| Dec 19, 2024 | 4.98 | -0.07 | -1.39% | 5.05 | 5.10 | 4.90 |
| Dec 18, 2024 | 5.01 | -0.26 | -4.93% | 5.27 | 5.33 | 4.91 |
| Dec 17, 2024 | 5.24 | 0.03 | 0.58% | 5.21 | 5.46 | 5.04 |
| Dec 16, 2024 | 5.32 | 0.07 | 1.33% | 5.25 | 5.51 | 5.14 |
| Dec 13, 2024 | 5.36 | -0.16 | -2.90% | 5.52 | 5.67 | 5.00 |
| Dec 12, 2024 | 5.64 | -0.05 | -0.88% | 5.69 | 5.73 | 5.50 |
| Dec 11, 2024 | 5.86 | 0.33 | 5.97% | 5.53 | 5.88 | 5.45 |
| Dec 10, 2024 | 5.54 | 0.15 | 2.78% | 5.39 | 5.65 | 5.33 |
| Dec 9, 2024 | 5.52 | -0.08 | -1.43% | 5.60 | 5.74 | 5.50 |
| Dec 6, 2024 | 5.56 | 0.07 | 1.28% | 5.49 | 5.73 | 5.47 |
| Dec 5, 2024 | 5.56 | -0.02 | -0.36% | 5.58 | 5.79 | 5.50 |
| Dec 4, 2024 | 5.56 | 0.01 | 0.18% | 5.55 | 5.73 | 5.55 |
| Dec 3, 2024 | 5.58 | -0.04 | -0.71% | 5.62 | 5.71 | 5.49 |
| Dec 2, 2024 | 5.76 | 0.36 | 6.67% | 5.40 | 5.80 | 5.40 |
| Nov 29, 2024 | 5.44 | 0.00 | 0.00% | 5.44 | 5.55 | 5.39 |
| Nov 27, 2024 | 5.48 | -0.27 | -4.70% | 5.75 | 5.84 | 5.44 |
| Nov 26, 2024 | 5.74 | 0.51 | 9.75% | 5.23 | 5.75 | 5.12 |
| Nov 25, 2024 | 5.24 | 0.11 | 2.14% | 5.13 | 5.45 | 5.13 |
| Nov 22, 2024 | 5.11 | 0.32 | 6.68% | 4.79 | 5.18 | 4.79 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Sage Therapeutic Company profile
About SAGE Therapeutics Inc
SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).
Equity composition
Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.
| Industry: | Bio Therapeutic Drugs |
215 1st St
CAMBRIDGE
MASSACHUSETTS 02142
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com